[{"id":"4c088dd4-b200-4ede-a7fc-cf87edb6f419","acronym":"REZILIENT2","url":"https://clinicaltrials.gov/study/NCT05967689","created_at":"2023-08-01T16:10:25.528Z","updated_at":"2024-07-02T16:35:02.952Z","phase":"Phase 2","brief_title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","source_id_and_acronym":"NCT05967689 - REZILIENT2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 10/20/2025","study_completion_date":" 10/20/2025","last_update_posted":"2024-05-17"},{"id":"a7d78ad7-64d9-4db4-b558-cc07349edbdc","acronym":"REZILIENT3","url":"https://clinicaltrials.gov/study/NCT05973773","created_at":"2023-08-03T15:09:38.478Z","updated_at":"2024-07-02T16:35:06.229Z","phase":"Phase 3","brief_title":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","source_id_and_acronym":"NCT05973773 - REZILIENT3","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 07/27/2026","primary_completion_date":" 07/27/2026","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2024-05-03"},{"id":"0b209ec8-a98e-41ee-a425-a93147024dd7","acronym":"CLN-081-001","url":"https://clinicaltrials.gov/study/NCT04036682","created_at":"2021-01-17T17:46:54.407Z","updated_at":"2024-07-02T16:35:07.435Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04036682 - CLN-081-001","lead_sponsor":"Cullinan Therapeutics Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zipalertinib (CLN-081)"],"overall_status":"Recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 10/31/2019","start_date":" 10/31/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-26"}]